ReviewBioMed research international2018
Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Chemical degradation of Human p38-MAPK reveals it as a potential host target to combat parasitic infections by Leishmania donovani and Plasmodium falciparum.Communications biology · 2026Article
- Clinical and PET/CT metabolic imaging characteristics across the evolving spectrum of visceral leishmaniasis and associated hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2026Article
- Early-warning prediction of visceral leishmaniasis mortality using a multivariate STL-deep learning hybrid approach on 20 years of monthly time series.Frontiers in public health · 2026Article
- Rare disease mimicking multisystem inflammatory syndrome in children.BMC pediatrics · 2025Article
- Impact of weather extremes on the spatiotemporal dynamics of visceral leishmaniasis in Brazil.PLoS neglected tropical diseases · 2025Article
- Comparative and systems analyses of Leishmania spp. non-coding RNAs through developmental stages.PLoS neglected tropical diseases · 2025Article
- In vitro and in vivo evaluation of the leishmanicidal and cytotoxic activities of chitosan and chitosan-amphotericin B.AMB Express · 2025Article
- Article
- Environmental Risk Factors for Visceral Leishmaniasis: An Analysis of Housing Types and Behavioral Factors in Baringo County, Kenya.The American journal of tropical medicine and hygiene · 2024Article
- Comparison of the Diagnostic Performances of Five Different Tests in Diagnosing Visceral Leishmaniasis in an Endemic Region of Ethiopia.Diagnostics (Basel, Switzerland) · 2024Article
- Bronchoalveolar Lavage Fluid Metagenomic Second-Generation Sequencing Assists in Guiding the Treatment of Visceral Leishmaniasis: A Case Report.Infection and drug resistance · 2024Article
- Article
- Evaluation of a Point-of-Need Molecular Diagnostic Tool Coupled with Rapid DNA Extraction Methods for Visceral Leishmaniasis.Diagnostics (Basel, Switzerland) · 2023Article
- Structural Modelling of Platelet Activating Factor Acetyl Hydrolase inInfection and drug resistance · 2023Article
- The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: Perception and future perspective.Frontiers in cellular and infection microbiology · 2023Review
- Visceral Leishmaniasis Associated with HIV Coinfection in Pará, Brazil.HIV/AIDS (Auckland, N.Z.) · 2023Article
- Case Report: FDG-PET/CT findings in co-infection of visceral leishmaniasis and chronic hepatitis B.Frontiers in cellular and infection microbiology · 2023Article
- Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.Frontiers in immunology · 2023Review
- Novel Selective and Low-Toxic Inhibitor ofBiomolecules · 2022Article
- Humoral and Cellular Immune Response in Asymptomatic Dogs with Visceral Leishmaniasis: A Review.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL), one of the deadliest parasitic diseases in the world, causes more than 50,000 human deaths each year and afflicts millions of people throughout South America, East Africa, South Asia, and Mediterranean Region. In 2015 the World Health Organization classified VL as a neglected tropical disease (NTD), prompting concentrated study of the VL epidemic using mathematical and simulation models. This paper reviews literature related to prevalence and prevention control strategies. More than thirty current research works were reviewed and classified based on VL epidemic study methods, including modeling approaches, control strategies, and simulation techniques since 2013. A summarization of these technical methods, major findings, and contributions from existing works revealed that VL epidemic research efforts must improve in the areas of validating and verifying VL mathematical models with real-world epidemic data. In addition, more dynamic disease control strategies must be explored and advanced simulation techniques must be used to predict VL pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.